Supernus Pharmaceuticals (SUPN) and Indivior (INDV) have agreed to merge in an all-stock transaction to form a central nervous system-focused biopharma, the companies announced, combining five growth-stage products and a combined market capitalization of $7.5bn.

AbbVie (ABBV) slightly reduced its 2026 earnings forecast to account for its planned acquisition of Apogee Therapeutics, even as the drugmaker surpassed second-quarter expectations on the back of robust immunology drug sales.

Vertex Pharmaceuticals (VRTX) raised the upper end of its full-year revenue forecast, citing robust demand across its cystic fibrosis portfolio after second-quarter sales came in ahead of Wall Street expectations.

Moderna (MRNA) posted stronger-than-expected second-quarter revenue, buoyed by vaccine partnership payments and overseas sales of its COVID-19 shot, as the company awaits a decision that could mark the most significant expansion of its mRNA platform since the pandemic.

AstraZeneca (AZN) shares fell sharply after reports emerged of merger talks with US rival Bristol Myers Squibb (BMY), with investors delivering a swift verdict that the British pharmaceutical giant has little need for a deal that would create one of the world's largest drugmakers.

Shares of Alnylam Pharmaceuticals (ALNY) hit a 52-week low of $273.03 last month, extending a steep decline that has seen the RNAi drug developer shed nearly 29% of its value since the start of the year.

Merck (MRK) has signed voluntary licensing agreements with seven generic drug manufacturers to produce and sell lower-cost versions of its experimental once-monthly oral HIV pill, alimatravir, across 129 low- and lower-middle-income countries — an unusually early move that comes while the drug is still in late-stage clinical development.

According to government data, the number ‌of confirmed ​Ebola ​cases in ⁠the ​Democratic ​Republic of Congo ​has ​increased to ‌3,200, ⁠including 1,405 deaths.

AstraZeneca (AZN) said that its rare disease therapy Ultomiris failed to meet its primary endpoint in a late-stage trial enrolling adults with a serious blood vessel complication that can arise following stem cell transplants, adding to a string of clinical setbacks that have raised questions about the company's trial design capabilities.

India's Cipla (CIPL) posted a bigger-than-expected fall in first-quarter profit, logging its third consecutive quarterly decline as muted sales of a generic cancer drug and US supply disruptions tied to tumor treatment lanreotide weighed on results.

Novo Nordisk (NVO) said it is seeking a preliminary US court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly (LLY), escalating a legal battle between the two dominant players in the lucrative weight-loss drug market.

Amgen (AMGN) said it had submitted new evidence to the Food and Drug Administration as it seeks a formal hearing to challenge the proposed withdrawal of Tavneos, its treatment for a rare autoimmune condition that damages blood vessels, from the U.S. market.

West Pharmaceutical Services (WST) raised its annual profit and revenue forecasts after strong demand for components used in injectable drugs — including treatments for diabetes and obesity — helped the company beat second-quarter estimates, sending its shares up nearly 6 percent in morning trading.

BridgeBio Pharma (BBIO) said the US Food and Drug Administration has accepted its New Drug Application for encaleret, an oral therapy for autosomal dominant hypocalcemia type 1, with a target action date of May 8, 2027.

Argenx (ARGX) has agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, adding the experimental autoimmune therapy FB102 to its portfolio.

Roche (RHHBY) has unveiled plans for a pivotal trial of its experimental Alzheimer's antibody, seeking to demonstrate it can prevent symptoms from developing as the Swiss drugmaker races Eli Lilly (LLY) and Japan's Eisai (ESAIY) to push the disease's treatment frontier from therapy into prevention.

AstraZeneca (AZN) has agreed to pay $600 million upfront to license a lung cancer treatment from China's Dizal Pharmaceutical (688192.SS), sending shares in the Shanghai-listed spinoff surging 20 percent.

Biogen (BIIB) said that the lowest dose of its experimental Alzheimer's drug diranersen reduced cognitive decline across five of six standard assessment tools and cut levels of a toxic brain protein by up to 65%, even as the treatment missed its primary goal in a mid-stage clinical trial.

Insulet (PODD), the maker of the Omnipod wearable insulin patch, has teamed up with mental health app Calm to launch a suite of free mindfulness resources tailored specifically to people living with diabetes, in what the companies describe as Calm's first integrated content partnership with a medical device manufacturer.

Yum Brands (YUM) said that its Taco Bell chain had pulled a limited number of items from select restaurant locations as a precautionary measure, even as US health officials stopped short of linking the fast-food chain to a widening outbreak of cyclosporiasis that has now spread across 34 states.